| PERON, Julien |
| Recruiting | 3 | 260 | Europe, Canada, Japan, RoW | Carboplatin-Paclitaxel, Dostarlimab | ARCAGY/ GINECO GROUP, GlaxoSmithKline | Endometrial Cancer | 04/26 | 10/29 | | |
MOST plus, NCT02029001: Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment |
|
|
| Recruiting | 2 | 900 | Europe | Nilotinib (400 mg BID), Open cohort, Everolimus (10 mg QD), Closed cohort, Sorafenib (400 mg BID), Lapatinib (1500 mg QD), Pazopanib (800 mg QD), Olaparib (300 mg BID), Durvalumab + Tremelimumab | Centre Leon Berard, National Cancer Institute, France | Malignant Solid Neoplasms | 01/26 | 10/27 | | |
NCT05733611: RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC |
|
|
| Active, not recruiting | 2 | 4 | NA | RP2, RP3, atezolizumab, bevacizumab | Replimune Inc., Roche Pharma AG | Refractory Metastatic Colorectal Cancer, pMMR, MSS | 01/27 | 03/27 | | |
NCT05733598: Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC |
|
|
| Recruiting | 2 | 30 | US | RP2, Bevacizumab, Avastin, Atezolizumab, Tecentriq | Replimune Inc., Roche Pharma AG | Hepatocellular Carcinoma | 12/27 | 07/28 | | |
Decrescendo, NCT04675827: De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade |
|
|
| Terminated | 2 | 139 | Europe, RoW | Pertuzumab and tratuzumab fixed dose combination, Adjuvant pertuzumab + trastuzumab FDC SC for 14 cycles, Fixed-dose combination of Perjeta and Herceptin for subcutaneous injection for 14 cycles, Trastuzumab emtansine, Adjuvant T-DM1 | Jules Bordet Institute, Breast International Group, Hoffmann-La Roche, International Drug Development Institute, Institut Curie | HER2-positive Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer, Node-negative Breast Cancer | 11/24 | 11/24 | | |
iDEFCO, NCT04015895: Implementation of a Tool to Identify Social Weaknesses in the Cancer Care Pathway |
|
|
| Terminated | N/A | 437 | Europe | DEFCO tool | Centre Hospitalier Universitaire de Saint Etienne, Ligue contre le cancer, France | Cancer | 05/22 | 06/23 | | |
OPERA, NCT04878692: Evaluation of a Cosmetic Product to Preserve Skin Conditions When Using Anti-EGFR Cancer Therapies |
|
|
| Not yet recruiting | N/A | 96 | Europe | Application of Onco-Rash cream, Application of Onco-Neutre cream | Hospices Civils de Lyon | Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Head and Neck Neoplasms | 07/22 | 07/22 | | |
COLLAT-COVID, NCT05932719: Multicentric Evaluation of COVID-19 Impact on Cancer Patients' Diagnostic and Management: Set-up of Indicators |
|
|
| Recruiting | N/A | 4000 | Europe | COLLAT-COVID is an observational study based on retrospective data issued from patients medial files. | Hospices Civils de Lyon | Hepatocellular Carcinoma, Peritoneal Carcinoma | 12/22 | 12/24 | | |
| Recruiting | N/A | 420 | Europe | FASTRACS intervention | Hospices Civils de Lyon | Breast Cancer | 12/23 | 12/23 | | |
| Recruiting | N/A | 139 | Europe | PRESTAGE | Hospices Civils de Lyon | Cancer, Oral Anticancer Drugs | 03/26 | 03/26 | | |
| Recruiting | N/A | 4975 | Europe, RoW | RP-1828 IMMUcan, RP-1759 AYA/TYA, RP-1843 Arcagen, RP-1920 BioRadon | European Organisation for Research and Treatment of Cancer - EORTC | All Tumor Types | 03/26 | 03/26 | | |
ONCOPRO, NCT03787056: Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients |
|
|
| Recruiting | N/A | 410 | Europe | Blood draws | Hospices Civils de Lyon | Cancer, Breast Cancer, Gastric Cancer, Renal Cancer, Prostate Cancer, Melanoma, Lung Cancer, Hepatocellular Cancer, Colorectal Cancer, Head and Neck Cancer, Pancreatic Cancer, Ovarian Cancer, Glioblastoma, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, B-cell Lymphoma | 01/28 | 01/28 | | |
MONITOR, NCT04605146: Impact of Telemonitoring for the Management of Side Effects in Patients with Melanoma, Lung or Renal Cancer, Treated with Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab Monotherapy |
|
|
| Recruiting | N/A | 100 | Europe | Tele-monitoring | Hospices Civils de Lyon | Melanoma, Lung Cancer, Renal Cancer | 11/28 | 11/28 | | |
IMMUCARE-BASE, NCT03989323: A Clinical and Biological Prospective Database of Patients Treated With Anticancer Immunotherapy and Follow up of Their Immune-related Adverse Events irAE |
|
|
| Recruiting | N/A | 2000 | Europe | Estimation of the incidence of the irAE | Hospices Civils de Lyon | Cancer | 07/29 | 07/29 | | |
| Smolenschi, Cristina |
Pan-MSI-ACSE, NCT06333314: Dostarlimab for Locally Advanced or Metastatic Cancer (non-colorectal/non-endometrial) with Tumor DMMR/MSI |
|
|
| Recruiting | 2 | 120 | Europe | Dostarlimab, Chemotherapy | UNICANCER, National Cancer Institute, France, GlaxoSmithKline | Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma, Adrenocortical Carcinoma, Neuroendocrine Carcinoma, Soft Tissue Sarcoma, Small Bowel Adenocarcinoma, Duodenum Adenocarcinoma, Gastric Adenocarcinoma | 10/28 | 09/30 | | |
NCT05733611: RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC |
|
|
| Active, not recruiting | 2 | 4 | NA | RP2, RP3, atezolizumab, bevacizumab | Replimune Inc., Roche Pharma AG | Refractory Metastatic Colorectal Cancer, pMMR, MSS | 01/27 | 03/27 | | |
NCT05733598: Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC |
|
|
| Recruiting | 2 | 30 | US | RP2, Bevacizumab, Avastin, Atezolizumab, Tecentriq | Replimune Inc., Roche Pharma AG | Hepatocellular Carcinoma | 12/27 | 07/28 | | |
